Home » Pipeline
Pipeline
September 7, 2020
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Cartesian Therapeutics | Descartes-30, RNA-engineered mesenchymal stem cell therapy | patients with moderate-to-severe ARDS, including that caused by COVID-19 | initiation of phase 1/2 trial |
| Aerpio Pharmaceuticals Quantum Leap Healthcare Collaborative |
razuprotafib | acute respiratory distress syndrome (ARDS) in severely ill COVID-19 patients | dosing of first patient in phase 2 trial |
| Orpheris | OP-101 | hospitalized adults with severe COVID-19 | enrollment of the first patients in phase 2 trial |
| Sound Pharmaceuticals | ebselen (SPI-1005) | adults with moderate or severe COVID-19 | approval to begin two phase 2 trials granted by the FDA |
| Vir Biotechnology GlaxoSmithKline | VIR-7831/ GSK4182136 | treatment of COVID-19 in patients who are at high risk of hospitalization | dosing of first patients in phase 2/3 trial |
| AstraZeneca | AZD1222 | COVID-19 vaccine | phase 3 trial expanded to the U.S. |
| Can-Fite Biopharma | piclidenoson | COVID-19 | IND approved by the FDA for phase 2 trial |
| INmune Bio | Quellor | immune mediated complications in COVID-19 patients | IND approved by the FDA for phase 2 trial |
| Gilead | Veklury (remdesivir) | all hospitalized patients with COVID-19 | Emergency Use Authorization (EUA) expanded by the FDA |
| Other Trials and Actions | |||
| Innovent | IBI112 | autoimmune disease | dosing of first patient in phase 1 trial |
| Shattuck Labs | SL-172154 | ovarian cancer | dosing of first patient in phase 1 trial |
| Transcenta Holding | TST001 | unresectable or metastatic solid tumors | dosing of first patient in phase 1 trial |
| Bicycle Therapeutics | BT1718 | patients with MT1-MMP-positive squamous non-small-cell lung cancer and a basket of other MT1-MMP-positive solid tumors | first patient dosed in phase 2a expansion portion of phase 1/2a trial |
| Treadwell Therapeutics | CFI-402411 | solid tumors | first patients dosed in phase 1/2 trial |
| Annovis Bio | ANVS401 | patients with early Alzheimer’s disease and Parkinson’s disease | initiation of patient dosing in phase 2a trial |
| Arena Pharmaceuticals | etrasimod | moderate-to-severe alopecia areata | dosing of first patient in phase 2 trial |
| Bicycle Therapeutics Oxurion |
THR-149 | diabetic macular edema | dosing of first patients in phase 2 trial |
| Embera NeuroTherapeutics | EMB-001 | cocaine use disorder | dosing of first patients in phase 2 trial |
| Chi-Med | HMPL-453 | advanced intrahepatic cholangiocarcinoma | initiation of phase 2 trial |
| POXEL | R-pioglitazone (PXL065) | patients with noncirrhotic biopsy-proven non-alcoholic steatohepatitis (NASH) | initiation of phase 2 trial |
| NGM Pharmaceuticals | aldafermin | biopsy-confirmed NASH with stage 2 (F2) and F3 liver fibrosis | patient enrollment complete in phase 2b trial |
| Provention Bio | PRV-015 | adult celiac patients not responding to a gluten-free diet | initiation of phase 2b trial |
| Madrigal Pharmaceuticals | resmetirom | patients with NASH and fibrosis that is diagnosed using noninvasive assessments | enrollment complete in phase 3 trial |
| Novan | SB206 | molluscum contagiosum | initiation of phase 3 trial |
| AEON Biopharma | ABP-450 | cervical dystonia | IND approved by the FDA |
| CStone Pharmaceuticals | sugemalimab (CS1001) | relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma | IND approved by the FDA |
| BioCryst Pharmaceuticals | BCX9930 | paroxysmal nocturnal hemoglobinuria | Orphan Drug designation granted by the FDA |
| Plus Therapeutics | Rhenium NanoLiposomes | recurrent glioblastoma | Orphan Drug designation granted by the FDA |
| Baxter | Theranova | kidney failure dialyzer enabling hemodialysis (HDx) therapy | de novo approval granted by the FDA |
| Innocoll Holdings | XARACOLL (bupivacaine HCl) Implant | acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair | approved by the FDA |
| Medtronic | MiniMed 770G hybrid closed loop system | insulin pump system for patients with type 1 diabetes | approved by the FDA |
| Roche | HIV-1/HIV-2 qualitative test | ability to differentiate between HIV-1 and HIV-2 | approved by the FDA |
